Overview of Managers’ Transactions at Orion Corporation
Orion Corporation has disclosed information in accordance with Market Abuse Regulation (EU) No 596/2014 regarding share transactions involving managers and their closely associated individuals.
Manager Information
Name: Liisa Hurme
Position: Chief Executive Officer
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 74913/13/8
Details of Transactions
Here are the specifics of the reported transactions:
NASDAQ HELSINKI LTD (XHEL)
Transaction date: Not specified
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details include:
(1): Volume: 5 Unit price: 46.7 EUR
(2): Volume: 100 Unit price: 46.7 EUR
(3): Volume: 200 Unit price: 46.7 EUR
(4): Volume: 6599 Unit price: 46.7 EUR
(5): Volume: 1596 Unit price: 46.7 EUR
(6): Volume: 329 Unit price: 46.6 EUR
Aggregated transactions (6):
Volume: 8829
Volume weighted average price: 46.69627 EUR
TURQUOISE (TRQX)
Transaction date: Not specified
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details include:
(1): Volume: 15 Unit price: 46.66 EUR
Aggregated transactions (1):
Volume: 15
Volume weighted average price: 46.66 EUR
CCXE
Transaction date: Not specified
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details include:
(1): Volume: 156 Unit price: 46.655 EUR
Aggregated transactions (1):
Volume: 156
Volume weighted average price: 46.655 EUR
About Orion Corporation
Orion is a Finnish pharmaceutical company that has been dedicated to enhancing well-being for over a century. We specialize in the development, manufacturing, and marketing of both human and veterinary pharmaceuticals, along with active pharmaceutical ingredients. Our extensive portfolio includes proprietary and generic medicines, as well as consumer health products. The primary focus areas of our pharmaceutical research and development are oncology and pain management. Orion's proprietary products are utilized to treat various conditions, including cancer, neurological disorders, and respiratory issues. In 2023, Orion reported net sales of EUR 1,190 million and employed approximately 3,600 individuals by the year's end. Our A and B shares are traded on Nasdaq Helsinki.
Frequently Asked Questions
What is the recent transaction reported by Orion Corporation?
The recent transaction involves significant disposals executed by CEO Liisa Hurme.
Who is Liisa Hurme?
Liisa Hurme is the Chief Executive Officer of Orion Corporation.
What type of securities were disposed of?
Shares of Orion Corporation were disposed of in the transactions mentioned.
What venues were involved in the transactions?
The transactions occurred on NASDAQ HELSINKI LTD, TURQUOISE, and CCXE.
How does Orion Corporation contribute to healthcare?
Orion develops and manufactures pharmaceuticals and health products, focusing on improving well-being for over a century.